期刊
MULTIPLE SCLEROSIS JOURNAL
卷 19, 期 5, 页码 605-612出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458512460605
关键词
Interferon; patient assessment; relapsing-remitting multiple sclerosis; scoring system; treatment response
资金
- Merck Serono SA of Geneva, Switzerland
- Bayer Schering Pharma
- Merck Serono
- Teva Pharmaceutical Industries Ltd.
- Sanofi-Aventis
- Biogen Idec
- Novartis
- Italian MS Society
Background: We employed clinical and magnetic resonance imaging (MRI) measures in combination, to assess patient responses to interferon in multiple sclerosis. Objective: To optimize and validate a scoring system able to discriminate responses to interferon treatment in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Our analysis included two large, independent datasets of RRMS patients who were treated with interferons that included 4-year follow-up data. The first dataset (training set) comprised of 373 RRMS patients from a randomized clinical trial of subcutaneous interferon beta-1a. The second (validation set) included an observational cohort of 222 RRMS patients treated with different interferons. The new scoring system, a modified version of that previously proposed by Rio et al., was first tested on the training set, then validated using the validation set. The association between disability progression and risk group, as defined by the score, was evaluated by Kaplan Meier survival curves and Cox regression, and quantified by hazard ratios (HRs). Results: The score (0-3) was based on the number of new T2 lesions (>5) and clinical relapses (0,1 or 2) during the first year of therapy. The risk of disability progression increased with higher scores. In the validation set, patients with score of 0 showed a 3-year progression probability of 24%, while those with a score of 1 increased to 33% (HR = 1.56; p = 0.13), and those with score greater than or equal to 2 increased to 65% (HR = 4.60; p < 0.001). Conclusions: We report development of a simple, quantitative and complementary tool for predicting responses in interferon-treated patients that could help clinicians make treatment decisions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据